Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
CORONADO, Calif. — Despite recent advances in the treatment of cutaneous squamous cell carcinoma (SCC), a lack of consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback